<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04998331</url>
  </required_header>
  <id_info>
    <org_study_id>C25023</org_study_id>
    <nct_id>NCT04998331</nct_id>
  </id_info>
  <brief_title>A Spanish Medical Record Review of Adults With Relapsed or Refractory CD30+ Malignancies When Re-treated With Brentuximab-vedotin</brief_title>
  <acronym>BELIEVE</acronym>
  <official_title>Effectiveness and Safety for Re-treatment With Brentuximab-Vedotin (BV) in Patients With Relapsed/Refractory (R/R) CD30+ Malignancies: a Retrospective Medical Chart Review Study in Spain</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Takeda</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Takeda</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Participants in the study are adults with CD30-positive malignancies which include classical&#xD;
      Hodgkin lymphoma (cHL), cutaneous T-cell lymphoma (CTCL): mycosis fungoides (MF) or primarily&#xD;
      cutaneous anaplastic large cell lymphoma (pcALCL), or systemic anaplastic large cell lymphoma&#xD;
      (sALCL).&#xD;
&#xD;
      The main aims of the study are as follows:&#xD;
&#xD;
        -  to learn about the response rates of participants with relapsed or refractory CD30+&#xD;
           malignancies when re-treated with BV.&#xD;
&#xD;
        -  to check for side effects from re-treatment with BV.&#xD;
&#xD;
      The study will take place in hospitals in Spain.&#xD;
&#xD;
      The study doctors will review each participant's medical record at least 6 months after&#xD;
      finishing the last dose of re-treatment with BV. This study is about collecting existing&#xD;
      information only; participants will not receive treatment or need to visit a study doctor&#xD;
      during this study.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is an observational, non-interventional, retrospective study in participants with R/R&#xD;
      CD30 positive cHL, CTCL (MF and pcALCL) and sALCL who have previously achieved a CR or PR&#xD;
      with BV treatment and subsequently experienced disease progression or participants with high&#xD;
      risk of relapse after ASCT were administered BV retreatment.&#xD;
&#xD;
      This study will assess the efficacy and safety of BV retreatment in the Spanish population in&#xD;
      real-world clinical practice. The study will enroll approximately 35 participants.&#xD;
&#xD;
      The data will be collected and recorded from the medical record of participants and also&#xD;
      recorded in electronic case report forms (e-CRFs). All the participants will be assigned to a&#xD;
      single observational cohort:&#xD;
&#xD;
      â€¢ Participants With CD30-positive Lymphoma&#xD;
&#xD;
      This multi-center trial will be conducted in Spain. The overall duration of the study will be&#xD;
      approximately 24 months (12 months for medical chart review and 12 until publication&#xD;
      submission).&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">October 29, 2021</start_date>
  <completion_date type="Anticipated">June 30, 2022</completion_date>
  <primary_completion_date type="Anticipated">May 31, 2022</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Retrospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Overall Response Rate (ORR) as Assessed by Investigator Based on Positron Emission Tomography/Computerized Tomography (PET/CT) Status</measure>
    <time_frame>Up to 6 months post-index date or death, whatever come first</time_frame>
    <description>ORR is the percentage of participants whose best overall response (graded by favorability in the order of clinical response [CR], partial response [PR], stable disease [SD], progressive disease [PD], and not evaluable [NE]) from initiation of BV retreatment to the discontinuation or end of treatment according to response criteria is either CR or PR. ORR will be assessed by investigator using 5-point scale for visually assessing response on the pre and end-of-treatment PET/CT scans. The 5-point scale ranges from: 1 (No uptake), 2 (Uptake less than or equal to [&lt;=] mediastinum), 3 (Uptake greater than [&gt;] mediastinum but &lt;=liver), 4 (Uptake moderately &gt;liver), and 5 (Uptake markedly higher than liver and/no new lesions). Total score ranges from 0-5. In case of unavailability of PET/CT scans, ORR will be assessed as per Revised Criteria for Response Assessment for Malignant Lymphoma. Index date: eligible participants who start BV as retreatment.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants Reporting one or More Adverse Events (AEs)</measure>
    <time_frame>Up to 12 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Duration of Response (DOR) Based on PET/CT Status</measure>
    <time_frame>Up to 6 months post-index date or death, whatever come first)</time_frame>
    <description>DOR will be calculated as the time (months) from the first documentation of a confirmed CR or PR (whichever is first recorded) to the date of objective PD or death from any cause, whichever is earliest. DOR will be assessed by investigator using 5-point scale for visually assessing response on the pre and end-of-treatment PET/CT scans. The 5-point scale ranges from: 1 (No uptake), 2 (Uptake &lt;=mediastinum), 3 (Uptake &gt;mediastinum but &lt;=liver), 4 (Uptake moderately &gt;liver), and 5 (Uptake markedly higher than liver and/no new lesions). Total score ranges from 0-5. In case of unavailability of PET/CT scans, DOR will be assessed as per Revised Criteria for Response Assessment for Malignant Lymphoma. Index date: eligible participants who start BV as retreatment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Survival (OS)</measure>
    <time_frame>From the index date to the date of death from any cause or end of follow-up (up to 6 months)</time_frame>
    <description>OS will be calculated as time (months) from the index date (date of initiation of BV as retreatment) to the date of death from any cause or end of follow-up. Participants alive at the end of the study period will be censored. Index date: eligible participants who start BV as retreatment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With Complete Response Based on PET/CT Status</measure>
    <time_frame>At the end of retreatment (up to 6 months post-index date or death, whatever come first)</time_frame>
    <description>Complete response will be assessed by investigator using 5-point scale for visually assessing response on the pre and end-of-treatment PET/CT scans. The 5-point scale ranges from: 1 (No uptake), 2 (Uptake &lt;=mediastinum), 3 (Uptake &gt;mediastinum but &lt;=liver), 4 (Uptake moderately &gt;liver), and 5 (Uptake markedly higher than liver and/no new lesions). Total score ranges from 0-5. In case of unavailability of PET/CT scans, complete response will be assessed as per Revised Criteria for Response Assessment for Malignant Lymphoma. Index date: eligible participants who start BV as retreatment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Clinical Response (CR or PR)</measure>
    <time_frame>From the index date to the date of documented CR or PR (up to 6 months)</time_frame>
    <description>Time to clinical response will be calculated from the date of index date (date of initiation of BV as retreatment) to the date of documented CR or PR. Index date: eligible participants who start BV as retreatment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Best Response</measure>
    <time_frame>From the index date to first documentation of best response documented (up to 6 months)</time_frame>
    <description>Time to best response will be calculated as the time from the index date (date of initiation of BV as retreatment) to first documentation of best response documented. Tumor response will be based on tumour assessments carried out as per local practice. Index date: eligible participants who start BV as retreatment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Treatment Failure (TTF)</measure>
    <time_frame>From the index date to first documentation of objective tumor progression or the day of death due to all causes (up to 6 months)</time_frame>
    <description>TTF will be calculated as the time from the index date (date of initiation of BV as retreatment) to first documentation of objective tumor progression or the day of death due to all causes whichever comes earlier. Tumor response will be based on tumour assessments carried out as per local practice. Index date: eligible participants who start BV as retreatment.</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">35</enrollment>
  <condition>Hodgkin Disease</condition>
  <condition>Lymphoma, T-Cell, Cutaneous</condition>
  <arm_group>
    <arm_group_label>Participants With CD30-positive Lymphoma</arm_group_label>
    <description>All participants diagnosed with relapsed/refractory (R/R) cHL, CTCL (mycosis fungoides [MF] and cutaneous anaplastic large cell lymphoma [pcALCL]) and sALCL with CD30 positive, and who have previously achieved a CR or PR with BV treatment and subsequently experienced disease progression/relapse or participants who have a high risk of relapse post autologous stem cell transplantation (ASCT) and were administered BV retreatment will be observed retrospectively from their initiation of BV treatment until participant's inclusion date in the study or until treatment discontinuation due to toxicities or any cause. All study data will be collected retrospectively from the medical records.</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>No Intervention</intervention_name>
    <description>This is a non-interventional study.</description>
    <arm_group_label>Participants With CD30-positive Lymphoma</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Participants with R/R cHL, CTCL (MF and pcALCL) and sALCL or with consolidated cHL with&#xD;
        CD30 positive, who have previously experienced a CR or PR with first BV treatment and&#xD;
        subsequently experienced disease progression or relapse were administered BV retreatment&#xD;
        will be included in this study.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Histologically confirmed cHL, CTCL (MF and pcALCL) or sALCL with CD30 positive.&#xD;
&#xD;
          2. Previously treated with BV containing regimen, with evidence of objective response&#xD;
             (determined by having achieved CR or PR), and subsequent disease progression or&#xD;
             relapse after discontinuing treatment BV retreatment.&#xD;
&#xD;
          3. Participants with data of disease relapse or progression greater than or equal to (&gt;=)&#xD;
             6 months since the last dose of the first treatment with BV.&#xD;
&#xD;
          4. Participant with data available at the participating site since diagnosis of cHL, CTCL&#xD;
             (MF and pcALCL) or sALCL.&#xD;
&#xD;
          5. Having received at least, two doses of BV as retreatment and having follow up&#xD;
             information available at the site for a minimum period of six months or until death.&#xD;
&#xD;
          6. Re-retreatment (in the case that retreatment of BV was administered after discontinued&#xD;
             retreatment of BV described above) is handled as a set of retreatments.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        1. Participants who does not freely consent to participate in the study (if applicable).&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Study Director</last_name>
    <role>Study Director</role>
    <affiliation>Takeda</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Takeda Contact</last_name>
    <phone>+1-877-825-3327</phone>
    <email>medinfoUS@takeda.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Hospital General Vega Baja</name>
      <address>
        <city>San Bartolome</city>
        <state>Alicante</state>
        <zip>03314</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Site Contact</last_name>
      <phone>+34 966 74 90 00</phone>
      <email>acantalapiedra1@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Fernanda Ibanez Camacho</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario de Alava</name>
      <address>
        <city>Gasteiz / Vitoria</city>
        <state>Araba</state>
        <zip>01009</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Site Contact</last_name>
      <phone>+34 945 00 70 00</phone>
      <email>ernesto.perezpersona@osakidetza.eus</email>
    </contact>
    <investigator>
      <last_name>Ernesto Perez</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Ico Hospitalet</name>
      <address>
        <city>L'Hospitalet de Llobregat</city>
        <state>Barcelona</state>
        <zip>08908</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Site Contact</last_name>
      <phone>+34 932 60 77 33</phone>
      <email>asureda@iconcologia.net</email>
    </contact>
    <investigator>
      <last_name>Anna Sureda</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Galdakao</name>
      <address>
        <city>Galdakao</city>
        <state>Bizkaia</state>
        <zip>48960</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Site Contact</last_name>
      <phone>+34 944 00 70 00</phone>
      <email>eukenegainza@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Eukene Gainza</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Donostia</name>
      <address>
        <city>Donostia</city>
        <state>Gipuzkoa</state>
        <zip>20014</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Site Contact</last_name>
      <phone>+34 943 00 70 00</phone>
      <email>izaskun.zeberioetxetxipia@osakidetza.eus</email>
    </contact>
    <investigator>
      <last_name>Izaskun Zeberio</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Gran Canaria Doctor Negrin</name>
      <address>
        <city>Las Palmas de Gran Canaria</city>
        <state>Gran Canarias</state>
        <zip>35010</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Site Contact</last_name>
      <phone>+34 928 45 00 00</phone>
      <email>dagubuj@gobiernodecanarias.org</email>
    </contact>
    <investigator>
      <last_name>David Aguiar</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Son Espases</name>
      <address>
        <city>Palma de Mallorca</city>
        <state>Mallorca</state>
        <zip>07120</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Site Contact</last_name>
      <phone>+34 871 20 50 00</phone>
      <email>antoniom.gutierrez@ssib.es</email>
    </contact>
    <investigator>
      <last_name>Antonio Gutierrez</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Nuestra Senora de Candelaria</name>
      <address>
        <city>Santa Cruz de Tenerife</city>
        <state>Tenerife</state>
        <zip>38010</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Site Contact</last_name>
      <phone>+34 922 60 20 00</phone>
      <email>carolhdez82@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Carolina Hernandez</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Del Mar</name>
      <address>
        <city>Barcelona</city>
        <zip>08003</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Site Contact</last_name>
      <phone>+34 932 48 30 00</phone>
      <email>bsanchezgonzalez@parcdesalutmar.cat</email>
    </contact>
    <investigator>
      <last_name>Blanca Sanchez-Gonzalez</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Vall D'Hebron Universitari</name>
      <address>
        <city>Barcelona</city>
        <zip>08035</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Site Contact</last_name>
      <phone>+34 934 89 30 00</phone>
      <email>ccarpio@vhebron.net</email>
    </contact>
    <investigator>
      <last_name>Cecilia Carpio</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Clinic I Provincial De Barcelona</name>
      <address>
        <city>Barcelona</city>
        <zip>08036</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Site Contact</last_name>
      <phone>+34 932 27 54 00</phone>
      <email>cmarti@clinic.cat</email>
    </contact>
    <investigator>
      <last_name>Carmen Martinez</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Santa Creu I Sant Pau</name>
      <address>
        <city>Barcelona</city>
        <zip>08041</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Site Contact</last_name>
      <phone>+34 932 91 90 00</phone>
      <email>snovelli@santpau.cat</email>
    </contact>
    <investigator>
      <last_name>Silvana Novelli</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Puerta del Mar</name>
      <address>
        <city>Cadiz</city>
        <zip>11009</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Site Contact</last_name>
      <phone>+34 956 00 21 00</phone>
      <email>fjcapote@hotmail.es</email>
    </contact>
    <investigator>
      <last_name>Francisco Javier Capote</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario de Jerez</name>
      <address>
        <city>Cadiz</city>
        <zip>11407</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Site Contact</last_name>
      <phone>+34 956 03 20 00</phone>
      <email>mjberruezo@hotmail.com</email>
    </contact>
    <investigator>
      <last_name>Maria Jose Berruezo</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario De La Princesa</name>
      <address>
        <city>Madrid</city>
        <zip>28006</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Site Contact</last_name>
      <phone>+34 915 20 22 00</phone>
      <email>jimenacannata@yahoo.es</email>
    </contact>
    <investigator>
      <last_name>Jimena Cannata</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Sanitas La Zarzuela</name>
      <address>
        <city>Madrid</city>
        <zip>28023</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Site Contact</last_name>
      <phone>+34 915 85 80 00</phone>
      <email>dgarciabe@sanitas.es</email>
    </contact>
    <investigator>
      <last_name>Daniel Garcia Belmonte</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Infanta Leonor</name>
      <address>
        <city>Madrid</city>
        <zip>28031</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site Contact</last_name>
      <phone>+34 913 85 48 97</phone>
      <email>jahr_jahr2006@yahoo.es</email>
    </contact>
    <investigator>
      <last_name>Maria Stefania Infante</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Ramon y Cajal</name>
      <address>
        <city>Madrid</city>
        <zip>28034</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Site Contact</last_name>
      <phone>+34 913 36 80 00</phone>
      <email>jljimenez@salud.madrid.org</email>
    </contact>
    <investigator>
      <last_name>Javier Lopez-Jimenez</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Fundacion Jimenez Diaz</name>
      <address>
        <city>Madrid</city>
        <zip>28040</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Site Contact</last_name>
      <phone>+34 915 50 48 00</phone>
      <email>dmori1985@hotmail.com</email>
    </contact>
    <investigator>
      <last_name>Daniel Morillo</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario 12 De Octubre</name>
      <address>
        <city>Madrid</city>
        <zip>28041</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Site Contact</last_name>
      <phone>+34 913 90 80 00</phone>
      <email>antonia.rodriguez@salud.madrid.org</email>
    </contact>
    <investigator>
      <last_name>Antonia Rodriguez</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital. Universitario 12 De Octubre</name>
      <address>
        <city>Madrid</city>
        <zip>28041</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Site Contact</last_name>
      <phone>+34 913 90 80 00</phone>
      <email>pablo.ortiz@salud.madrid.org</email>
    </contact>
    <investigator>
      <last_name>Pablo Ortiz</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Regional Universitario Malaga</name>
      <address>
        <city>Malaga</city>
        <zip>29010</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Site Contact</last_name>
      <phone>+34 951 29 00 00</phone>
      <email>mespesoh@hotmail.com</email>
    </contact>
    <investigator>
      <last_name>Manuel Espeso</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital General Universitario Morales Meseguer</name>
      <address>
        <city>Murcia</city>
        <zip>30008</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Site Contact</last_name>
      <phone>+34 968 36 09 00</phone>
      <email>jjcaracoles@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Jose Javier Sanchez Blanco</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Complejo Hospitalario Universitario de Pontevedra</name>
      <address>
        <city>Pontevedra</city>
        <zip>36071</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Site Contact</last_name>
      <phone>+34 986 80 00 00</phone>
      <email>maria.lourdes.amador.barciela@sergas.es</email>
    </contact>
    <investigator>
      <last_name>Lourdes Amador</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Clinico Universitario Salamanca</name>
      <address>
        <city>Salamanca</city>
        <zip>37007</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Site Contact</last_name>
      <phone>+34 923 29 11 00</phone>
      <email>rgarciasanz@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Ramon Garcia-Sanz</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Virgen Macarena</name>
      <address>
        <city>Sevilla</city>
        <zip>41009</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Site Contact</last_name>
      <phone>+34 955 00 80 00</phone>
      <email>sortegonalcaide@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Sergio Ortegon</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Virgen de Valme</name>
      <address>
        <city>Sevilla</city>
        <zip>41014</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Site Contact</last_name>
      <phone>+34 955 01 50 00</phone>
      <email>eriosh@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Eduardo Rios</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Universitari I Politecnic La Fe De Valencia</name>
      <address>
        <city>Valencia</city>
        <zip>46026</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Site Contact</last_name>
      <phone>+34 961 24 40 00</phone>
      <email>jgcodina@outlook.es</email>
    </contact>
    <investigator>
      <last_name>Jose Gomez-Codina</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Rio Hortega</name>
      <address>
        <city>Valladolid</city>
        <zip>47012</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Site Contact</last_name>
      <phone>+34 983 42 04 00</phone>
      <email>fernandaibanezcamacho@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Alberto Cantalapiedra</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital De Dia Quironsalud Zaragoza</name>
      <address>
        <city>Zaragoza</city>
        <zip>50012</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Site Contact</last_name>
      <phone>+34 976 57 90 00</phone>
      <email>giraldocastellano@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Pilar Giraldo</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <link>
    <url>https://clinicaltrials.takeda.com/study-detail/6112d601cd353f0032b9205a</url>
    <description>To obtain more information on the study, click here/on this link</description>
  </link>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>August 6, 2021</study_first_submitted>
  <study_first_submitted_qc>August 6, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">August 10, 2021</study_first_posted>
  <last_update_submitted>November 4, 2021</last_update_submitted>
  <last_update_submitted_qc>November 4, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 11, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Drug Therapy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hodgkin Disease</mesh_term>
    <mesh_term>Lymphoma, T-Cell</mesh_term>
    <mesh_term>Lymphoma, T-Cell, Cutaneous</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Takeda provides access to the de-identified individual participant data (IPD) for eligible studies to aid qualified researchers in addressing legitimate scientific objectives (Takeda's data sharing commitment is available on https://clinicaltrials.takeda.com/takedas-commitment?commitment=5). These IPDs will be provided in a secure research environment following approval of a data sharing request, and under the terms of a data sharing agreement.</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Statistical Analysis Plan (SAP)</ipd_info_type>
    <ipd_info_type>Informed Consent Form (ICF)</ipd_info_type>
    <ipd_info_type>Clinical Study Report (CSR)</ipd_info_type>
    <ipd_access_criteria>IPD from eligible studies will be shared with qualified researchers according to the criteria and process described on https://vivli.org/ourmember/takeda/. For approved requests, the researchers will be provided access to anonymized data (to respect patient privacy in line with applicable laws and regulations) and with information necessary to address the research objectives under the terms of a data sharing agreement.</ipd_access_criteria>
    <ipd_url>https://vivli.org/ourmember/takeda/</ipd_url>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

